東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Endothelial cell signaling in normal...

Murphy, Danielle A.

Linked to FindBook

Google Book

Amazon

博客來

Endothelial cell signaling in normal and malignant tissues.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Endothelial cell signaling in normal and malignant tissues./
Author:	Murphy, Danielle A.
Description:	150 p.
Notes:	Adviser: William M. F. Lee.
Contained By:	Dissertation Abstracts International67-03B.
Subject:	Biology, Cell. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3211116
ISBN:	9780542597213

Endothelial cell signaling in normal and malignant tissues.
Murphy, Danielle A.

Endothelial cell signaling in normal and malignant tissues. - 150 p.

Adviser: William M. F. Lee.

Thesis (Ph.D.)--University of Pennsylvania, 2006.

Angiogenesis is induced by an increase in pro-angiogenic factors in tissue microenvironments, which stimulates transduction of signals that promote endothelial cell proliferation, chemotaxis, and survival. Endothelial cells regulate neovascularization through activation of the Raf-MEK-ERK and PI3K-AKT pathways. During tumor angiogenesis, it is unknown what mechanisms regulate neovascularization and endothelial cell survival. Addressing these issues, murine organs and tumors were investigated for activation of ERK and AKT in their vasculatures. Tumors expressed activated ERK in more vessels than normal murine organs. In contrast, AKT was activated in both tumor and normal endothelium. To examine the effects of inhibition of ERK activation, tumors were treated with sorafenib, a Raf kinase inhibitor. Following treatment, there was decreased ERK activation. On the other hand, AKT activation remained unchanged in tumor vasculature of three tumor models after sorafenib administration. Changes in endothelial cell signaling were accompanied by decreased tumor growth and inhibition of angiogenesis. These suggest that sorafenib controls tumor growth through decreased angiogenesis, which is regulated by ERK inhibition in tumor endothelia. Due to the restricted expression of activated ERK in tumor endothelium, and its decreased expression in tumor endothelium following sorafenib treatment and angiogenic inhibition, ERK activation may be a good biomarker for responses to sorafenib therapy. These studies highlight the importance of understanding endothelial cell signaling in the vasculature of both normal and tumor tissues in vivo. In gaining a better knowledge of activated pathways in endothelia, we can identify potential targets to inhibit pathological angiogenesis and ways to monitor angiogenic and antiangiogenic events.

ISBN: 9780542597213Subjects--Topical Terms:

1017686
Biology, Cell.

Endothelial cell signaling in normal and malignant tissues.
LDR:02733nam 2200289 a 45 001 965346
005 20110906
008 110906s2006 eng d
020 $a 9780542597213
035 $a (UnM)AAI3211116
035 $a AAI3211116
040 $a UnM $c UnM
100 1 $a Murphy, Danielle A. $3 1288121
245 1 0 $a Endothelial cell signaling in normal and malignant tissues.
300 $a 150 p.
500 $a Adviser: William M. F. Lee.
500 $a Source: Dissertation Abstracts International, Volume: 67-03, Section: B, page: 1286.
502 $a Thesis (Ph.D.)--University of Pennsylvania, 2006.
520 $a Angiogenesis is induced by an increase in pro-angiogenic factors in tissue microenvironments, which stimulates transduction of signals that promote endothelial cell proliferation, chemotaxis, and survival. Endothelial cells regulate neovascularization through activation of the Raf-MEK-ERK and PI3K-AKT pathways. During tumor angiogenesis, it is unknown what mechanisms regulate neovascularization and endothelial cell survival. Addressing these issues, murine organs and tumors were investigated for activation of ERK and AKT in their vasculatures. Tumors expressed activated ERK in more vessels than normal murine organs. In contrast, AKT was activated in both tumor and normal endothelium. To examine the effects of inhibition of ERK activation, tumors were treated with sorafenib, a Raf kinase inhibitor. Following treatment, there was decreased ERK activation. On the other hand, AKT activation remained unchanged in tumor vasculature of three tumor models after sorafenib administration. Changes in endothelial cell signaling were accompanied by decreased tumor growth and inhibition of angiogenesis. These suggest that sorafenib controls tumor growth through decreased angiogenesis, which is regulated by ERK inhibition in tumor endothelia. Due to the restricted expression of activated ERK in tumor endothelium, and its decreased expression in tumor endothelium following sorafenib treatment and angiogenic inhibition, ERK activation may be a good biomarker for responses to sorafenib therapy. These studies highlight the importance of understanding endothelial cell signaling in the vasculature of both normal and tumor tissues in vivo. In gaining a better knowledge of activated pathways in endothelia, we can identify potential targets to inhibit pathological angiogenesis and ways to monitor angiogenic and antiangiogenic events.
590 $a School code: 0175.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0307
690 $a 0379
690 $a 0992
710 2 0 $a University of Pennsylvania. $3 1017401
773 0 $t Dissertation Abstracts International $g 67-03B.
790 $a 0175
790 1 0 $a Lee, William M. F., $e advisor
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3211116